Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

NCT01445535 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

NIH

Sponsor class

Conditions

T-Cell Peripheral Lymphoma
Gamma Delta Hepatosplenic T-Cell Lymphoma
Subcutaneous Panniculitis-Like T-Cell Lymphoma
NK T-Cell Lymphoma

Interventions

BIOLOGICAL: Rituximab
DRUG: Etoposide
BIOLOGICAL: Siplizumab
DRUG: Prednisone
DRUG: Vincristine
DRUG: Cyclophosphamide
DRUG: Doxorubicin

Sponsor

National Cancer Institute (NCI)